Next Article in Journal
Overview of Antibody Drug Delivery
Next Article in Special Issue
Mesoporous Silica Nanoparticles: A Comprehensive Review on Synthesis and Recent Advances
Previous Article in Journal
Synthesis, Structure–Activity Relationships and In Vitro Toxicity Profile of Lactose-Based Fatty Acid Monoesters as Possible Drug Permeability Enhancers
Article Menu
Issue 3 (September) cover image

Export Article

Open AccessArticle
Pharmaceutics 2018, 10(3), 82;

Buspirone Nanovesicular Nasal System for Non-Hormonal Hot Flushes Treatment

The Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, P.O. Box 12065, Jerusalem 91120, Israel
Author to whom correspondence should be addressed.
Received: 6 June 2018 / Revised: 25 June 2018 / Accepted: 2 July 2018 / Published: 3 July 2018
(This article belongs to the Special Issue Smart Nanovesicles for Drug Targeting and Delivery)
Full-Text   |   PDF [1955 KB, uploaded 3 July 2018]   |  


The aim of this work was to design and characterize a new nanovesicular nasal delivery system (NDS) containing buspirone, and investigate its efficiency in an animal model for the treatment of hot flushes. The presence of multilamellar vesicles with a mean size distribution of 370 nm was evidenced by transition electron microscopy (TEM), cryo-scanning electron microscopy (Cryo-SEM), and dynamic light scattering (DLS) tests. Pharmacodynamic evaluation of the nasal treatment efficacy with the new system was carried out in ovariectomized (OVX) rat—an animal model for hot flushes—and compared with other treatments. We found that the nasal administration of a buspirone NDS resulted in a significant reduction in tail skin temperature (TST). This effect was not observed in the control buspirone-treated groups. Buspirone levels in the plasma and brain of nasally-treated normal rats were quantified and compared with those of rats that had received oral administration by a LC-MS/MS assay. A significantly higher bioavailability was achieved with the new treatment relative to an oral administration of the same drug dose. No pathological changes in the nasal cavity were observed following sub-chronic nasal administration of buspirone NDS. In conclusion, the data of our investigation show that buspirone in the new nanovesicular nasal carrier could be considered for further studies for the development of a treatment for the hot flushes ailment. View Full-Text
Keywords: nanovesicular nasal carrier; nasal delivery system; buspirone; hot flushes; ovariectomized rat nanovesicular nasal carrier; nasal delivery system; buspirone; hot flushes; ovariectomized rat

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Touitou, E.; Natsheh, H.; Duchi, S. Buspirone Nanovesicular Nasal System for Non-Hormonal Hot Flushes Treatment. Pharmaceutics 2018, 10, 82.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Pharmaceutics EISSN 1999-4923 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top